Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

NEOSCAN

GALLIUM CITRATE GA-67

Standard Dose
2mCi/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview NEOSCAN is listed in Drugs@FDA under application 017655 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient GALLIUM CITRATE GA-67 Form and strength INJECTABLE;INJECTION - 2mCi/ML Sponsor GE HEALTHCARE Submission history Latest submission status date: 1995-03-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview NEOSCAN is listed in Drugs@FDA under application 017655 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient GALLIUM CITRATE GA-67 Form and strength INJECTABLE;INJECTION - 2mCi/ML Sponsor GE HEALTHCARE Submission history Latest submission status date: 1995-03-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.